Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma

Powles, Thomas; H. O’Donnell, Peter; Massard, Christophe; Arkenau, Hendrik-Tobias; W. Friedlander, Terence; Hoimes, Christopher; Lee, Jae‐Lyun; Ong, Michael; S. Sridhar, Srikala; J. Vogelzang, Nicholas; Fishman, Mayer; Zhang, Jingsong; Srinivas, Sandy; Parikh, Jigar; Antal, Joyce; Jin, Xiaoping; Gupta, Ashok; Ben, Yong; M. Hahn, Noah

doi:10.1001/jamaoncol.2017.2411

Public

Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma

Published in JAMA Oncology • Aug 17, 2017

Authors:

Thomas Powles

Peter H. O’Donnell

Christophe Massard

Abstract

IMPORTANCE: The data reported herein were accepted for assessment by the US Food and Drug Administration for Biologics License Application under priority review to establish the clinical benefit of durvalumab as second-line therapy for locally advanced or metastatic urothelial carcinoma (UC), result...

Subject

Medicine

Durvalumab

Metastatic Urothelial Carcinoma

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!